OBJECTIVE Hodgkin and non-Hodgkin lymphoma patients are at high risk of experiencing anxiety because the clinical processes and therapies they undergo produce strong adverse effects. In this review we discuss the prevalence of anxiety among these patients and examine the methods used for data collection, intervention frequency, types of instruments used to recognize anxiety, and data collection purposes, both in Hodgkin and non-Hodgkin lymphoma survivors and patients being treated or diagnosed with these diseases. METHODS This systematic review and meta-analysis of the literature was carried out using the following sources: PubMed, Scopus, LILACS, and PsycINFO. RESULTS The meta-analysis sample was n = 2,138 and the overall prevalence of anxiety was 19% (95% CI [12%, 25%]). According to the Egger test, there were no publication biases and no studies were eliminated after the sensitivity analysis. The I2 for the heterogeneity analysis was 92.6%. CONCLUSIONS Hodgkin and non-Hodgkin lymphoma patients are vulnerable to suffering anxiety. It is important to focus on the psychological effect of anxiety during remission or current cancer treatments because they can affect patient outcomes. (PsycInfo Database Record (c) 2020 APA, all rights reserved).

中文翻译：

---

淋巴瘤的焦虑患病率：系统评价和荟萃分析。

目的霍奇金和非霍奇金淋巴瘤患者极易患上焦虑症，因为他们所经历的临床过程和疗法会产生强烈的不良反应。在这篇综述中，我们讨论了霍奇金和非霍奇金淋巴瘤幸存者以及接受治疗的患者中焦虑症的患病率，并研究了用于收集数据，干预频率，用于识别焦虑的仪器类型以及数据收集目的的方法。或被诊断出患有这些疾病。方法使用以下来源对文献进行系统的综述和荟萃分析：PubMed，Scopus，LILACS和PsycINFO。结果荟萃分析样本为n = 2138，焦虑总患病率为19％（95％CI [12％，25％]）。根据Egger检验，敏感性分析后，没有发表偏倚，也没有消除任何研究。异质性分析的I2为92.6％。结论霍奇金和非霍奇金淋巴瘤患者易患焦虑症。重要的是要关注缓解或当前癌症治疗期间焦虑的心理影响，因为它们会影响患者的预后。（PsycInfo数据库记录（c）2020 APA，保留所有权利）。